Qilian International Holding Group Ltd./$BGM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Qilian International Holding Group Ltd.
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
Ticker
$BGM
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
323
ISIN
KYG7307E1237
Website
BGM Metrics
BasicAdvanced
$2.2B
-
-$0.20
-
-
Price and volume
Market cap
$2.2B
52-week high
$17.17
52-week low
$8.38
Average daily volume
76K
Financial strength
Current ratio
3.392
Quick ratio
2.645
Interest coverage (TTM)
-0.88%
Profitability
EBITDA (TTM)
0.673
Gross margin (TTM)
16.39%
Net profit margin (TTM)
-5.75%
Operating margin (TTM)
-2.25%
Effective tax rate (TTM)
29.01%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-0.68%
Return on equity (TTM)
-3.43%
Valuation
Price to revenue (TTM)
3.447
Price to book
2.02
Price to tangible book (TTM)
2.26
Price to free cash flow (TTM)
-25.537
Free cash flow yield (TTM)
-3.92%
Free cash flow per share (TTM)
-46.87%
Growth
Revenue change (TTM)
-45.99%
Earnings per share change (TTM)
-81.48%
Bulls say / Bears say
BGM Group Ltd. has a strong balance sheet with zero debt and significant cash reserves, positioning it well for future investments and growth opportunities. (Simply Wall St)
The company's recent name change and ticker symbol update reflect a strategic rebranding, potentially enhancing its market presence and investor appeal. (PR Newswire)
BGM Group Ltd. has demonstrated a positive annual return of 119.2% in 2024, indicating strong market performance and investor confidence. (Alphacubator)
The company reported a net loss of $7.78 million for the fiscal year ended September 30, 2023, compared to a net income of $1.08 million the previous year, indicating financial challenges. (MarketScreener)
BGM Group Ltd. experienced a significant revenue decline of 52% over the past year, raising concerns about its ability to maintain market share and profitability. (Simply Wall St)
The company's low price-to-sales ratio suggests that investors may have low expectations for future revenue growth, potentially limiting stock appreciation. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Qilian International Holding Group Ltd. stock?
Qilian International Holding Group Ltd. (BGM) has a market cap of $2.2B as of July 01, 2025.
What is the P/E ratio for Qilian International Holding Group Ltd. stock?
The price to earnings (P/E) ratio for Qilian International Holding Group Ltd. (BGM) stock is 0 as of July 01, 2025.
Does Qilian International Holding Group Ltd. stock pay dividends?
No, Qilian International Holding Group Ltd. (BGM) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Qilian International Holding Group Ltd. dividend payment date?
Qilian International Holding Group Ltd. (BGM) stock does not pay dividends to its shareholders.
What is the beta indicator for Qilian International Holding Group Ltd.?
Qilian International Holding Group Ltd. (BGM) does not currently have a Beta indicator.